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Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase
inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study
were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented
patients with Alzheimer’s disease and related disorders (ADRD) before and after the use of CEIs or memantine, and
in age- and gender-matched controls patients with ADRD using no anti-dementia drugs; and 2) to determine
whether changes in CoV of stride time differed between CEIs or memantine.
Methods: A total of 120 demented patients with mild-to-moderate ADRD were prospectively included in this
pre-post quasi-experimental study with two intervention groups (43 patients taking CEIs, and 41 taking memantine)
and a control group (36 age- and gender matched patients without any anti-dementia drugs). CoV of stride time
and walking speed were measured with GAITRite® system while usual walking at steady state. Age, gender, number
of drugs daily taken, use of psychoactive drugs, body mass index and time between the two visits were also
recorded.
Results: There was no difference between groups for the time between baseline and follow-up assessments (232.9 ±
103.7 days for patients without anti-dementia drugs, 220.0 ± 67.5 days for patients with CEIs, 186.7 ± 96.2 days for
patients with memantine, P = 0.062). Patients with memantine had a lower (i.e., better) CoV of stride time at
follow-up assessment compared to those with CEIs (4.2 ± 2.4% versus 5.8 ± 4.2%, P = 0.010). Patients with memantine
had a greater decrease in CoV of stride time compared to those with CEIs (−1.90% versus 0.93%, P = 0.010) and
mixed-effects linear regressions showed that this decrease was specifically explained by memantine (P = 0.028).
Conclusions: Our results showed that patients with ADRD and treated with memantine, but not those with CEIs,
decreased their gait variability, and thus improved their gait safety (Trial registration number: NCT01315704).
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Acetylcholinesterase inhibitors (CEIs) (i.e., donepezil,
galantamine and rivastigimine) and NMDA receptor an-
tagonist (i.e., memantine) are symptomatic drugs for the
treatment of patients with Alzheimer’s disease and
related disorders (ADRD), respectively with mild-to-
moderate and moderate-to-severe stages [1-3]. The use
of these drugs has proved to temporarily stabilize and/
or to delay cognitive and functional declines in ADRD* Correspondence: olbeauchet@chu-angers.fr
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reproduction in any medium, provided the or[1,3]. A limited number of studies have highlighted that
these anti-dementia drugs may also improve gait per-
formance [4-7]. In particular, two studies have reported
a decrease in gait variability in demented patients using
either donepezil or memantine [5,7]. Gait variability is
defined as fluctuations in stride-to-stride intervals and
may be measured by the coefficient of variation (CoV =
[standard deviation/mean] × 100) of spatio-temporal
gait parameters [8]. Improvements of gait variability are
useful for patients since lower (i.e., better) gait variability
while walking at steady state self-selected pace illustrates
an efficient gait control and a safety gait [5-10]. For in-
stance, a low stride-to-stride variability of stride time -al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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depending on higher-levels gait control - has been as-
sociated with greater gait safety in demented patients
[5-11]. To date, CEIs-related improvement of gait per-
formance has been explained by enhancements of the
attention resource allocation involved in gait control
[4,5]. In parallel, memantine-related gait improvement
has been explained by its dopaminergic effect [5,7,12].
However, no comparison between CEIs- and memantine-
related improvements of gait variability has been per-
formed yet in demented patients. We hypothesized that
CEIs and memantine could reduce the CoV of stride time,
and that this anti-dementia drug-related changes in CoV
of stride time could be different between CEIs and mem-
antine because of different mechanisms of action. Indeed,
memantine has a cognitive and motor effect explained
respectively by a non-competitive antagonist action on
neuronal N-methyl-D-aspartate (NMDA)-type glutam-
ate and nicotinic acetylcholine receptors combined with
an agonist action on neuronal dopamine D2 receptors
[3]. In contrast, CEIs have only a cognitive effect ex-
plained by an inhibition of acetylcholinesterase enzyme
that increases both the level and duration of action of
acetylcholine [1,2]. The objectives of this study were to
1) quantify and compare mean values and CoV of stride
time in patients with ADRD before and after the use of
CEIs or memantine, and in age- and gender-matched
controls with ADRD using no anti-dementia drugs; and
2) to determine whether changes in CoV of stride time
differed between CEIs or memantine.
Methods
Participants and assessment
Between June 2011 and December 2012, 84 demented
patients with mild-to-moderate ADRD (mean age 82.2 ±
6.5 years; 65.5% female) with CEIs (n = 43) and meman-
tine (n = 41), and 36 age- and gender-matched controlled
demented patients with mild-to-moderate ADRD with-
out treatment (mean age 81.3 ± 5.5 years; 61.1% female)
were prospectively and consecutively included in this
quasi-experimental study (Trial registration number:
NCT01315704). The assignment in both intervention
groups (i.e., participants with CEIs and participants with
memantine) was not randomized and it was an open
label study. The choice of the anti-dementia drug was
based on the severity of the cognitive decline (mild-to-
moderate for CEIs, and moderate for memantine), con-
traindications and side effects of CEIs and memantine.
The age (plus or minus 2 years) and gender matching
were performed only on the control group (i.e., partici-
pants without anti-dementia drugs). Inclusion criteria
were outpatients visiting the memory clinic with a de
novo diagnosis of mild-to-moderate ADRD and at least
one follow-up visit with two gait analyses separated by atleast 6 months in the memory clinic of Angers University
Hospital, France. At baseline assessment, all participants
had no anti-dementia drugs. In addition, those receiving
an anti-dementia drug during the follow-up (i.e., the inter-
vention group) had an effective daily dose (i.e., at least
5 mg of donepezil, 16 mg galantamine, 9.6 mg rivastig-
mine patch, and 20 mg memantine) for at least 3 months.
Participants with co-prescription of cerebral vasodilata-
tors, renal failure, extrapyramidal rigidity of the upper
limbs (score above 2 on item 22 of the Unified Parkinson’s
Disease Rating Scale motor score) [13], acute medical ill-
ness within the past month, severe orthopaedic diagnoses,
depression (i.e., 4-item Geriatric Depression Scale ≥1)
[14], as well as those using walking aids and anticholiner-
gic medication were excluded. Four hundred and twelve
patients were followed during the period of inclusion and
219 (53.2%) met the selection criteria. Among this sub-
group, 143 (65.3%) took an anti-dementia drug but only
84 (38.4%) at an effective dose. Among the 76 (34.7%)
participants who did not take anti-dementia drugs, 36
(16.4%) were included based on the matching criteria.
Having a group of patients without anti-dementia drugs
was possible due to the 6-month period corresponding
to the delay of paraclinical investigations required for
the prescription of AD-specific treatment in the memory
clinic of Angers University Hospital. For each patient
included in the study and who had an anti-dementia
drug, one matched patient with no anti-dementia drugs
was included. All included participants after this process
of selection completed the study.
Participants included in the study underwent neuro-
logical examination, neuropsychological testing, and
brain imaging. In addition, age, gender, number of
drugs daily taken, use of psychoactive drugs (i.e., benzo-
diazepines, antidepressants or neuroleptics), height
(cm), weight (kg) and time (day) between the two visits
were recorded. The body mass index (kg/m2) was cal-
culated. The diagnoses of ADRD were made during
multidisciplinary meetings involving geriatricians, neu-
rologists and neuropsychologists. The diagnosis of
ADRD followed the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition and the National Insti-
tute of Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disor-
ders Association criteria [15]. The CoV of stride time,
calculated with the following formula CoV=[Standard
deviation/mean] × 100 (the stride time being the time
elapsed between the contact of two consecutive foot-
steps of the same foot), and walking speed were mea-
sured using GAITRite® system (GAITRite Gold
walkway, 972 cm long, active electronic surface area
792×610 cm, with a total of 29,952 pressure sensors,
scanning frequency 60 Hz, software version 3.8, CIR
System, Havertown, PA). The participants were asked to
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speed. Each participant completed one trial. Partici-
pants walked in a quiet, well-lit room wearing their own
footwear according to European guidelines for spatio-
temporal gait analysis in older adults [16].
Standard protocol approvals, registrations, and patient
consents
The study was conducted in accordance with the ethical
standards set forth in the Helsinki Declaration (1983).
The entire study protocol was approved by the local Ethical
Committee of Angers (France). Written informed con-
sent for participation in the study was obtained from all
participants.
Statistics
The participants’ baseline characteristics were summa-
rized using means and standard deviations or frequencies
and percentages, as appropriate. The normality of the pa-
rameters’ distribution was verified with a Shapiro-Francia
test before and after applying usual transformations to
normalize non-Gaussian variables. Participants were sepa-
rated into 3 groups: those without anti-dementia drugs,
those using CEIs, and those using memantine. First,
between-group comparisons were performed using analysis
of variance the Kruskal-Wallis, Mann–Whitney or Chi-
square tests, as appropriate. Second, anti-dementia drugs
effect (i.e., no drugs versus drugs), time effect (i.e., time
between before and after anti-dementia drugs use) and an
anti-dementia drugs effect X time effect interaction were
included as independent variables in a repeated analysis of
covariance (ANCOVA) to analyze their respective influ-
ence on CoV of stride time (dependent variable), with andTable 1 Characteristics and comparisons of the participants’ c






Age, mean ± SD (years) 81.3 ± 5.5 81.0 ± 6.6
Female gender, n (%) 22 (61.1) 30 (69.8)
BMI, mean ± SD (kg/m2) 26.9 ± 4.4 26.2 ± 4.9
Number of drugs daily taken, mean ± SD 6.2 ± 3.2 5.2 ± 3.3
Use psychoactive drugs†, n (%) 17 (47.2) 16 (37.2)
MMSE score‡ (/30 points), mean ± SD 20.8 ± 5.7 19.8 ± 4.6
Time between visits, mean ± SD (days) 232.9 ± 103.7 220.0 ± 67.5 1
Walking speed (cm/s), mean ± SD 68.3 ± 21.3 62.4 ± 21.3 6
CoV of stride time (%), mean ± SD
Before treatment 4.8 ± 2.2 4.9 ± 2.8
After treatment 5.4 ± 5.7 5.8 ± 4.2
CEIs: acetylcholinesterase inhibitors; BMI: body mass index; MMSE: Folstein's Mini-M
*: comparison based on analysis of variance Kruskal-Wallis test, Mann–Whitney or th
roleptics at baseline assessment; ‡: at baseline assessment (i.e., before treatment); Pwithout adjustment on baseline characteristics of partic-
ipants. Third, a mixed-effect linear regression model (with
Stata "xtmixed" command) using the same variables was
performed to specify which anti-dementia drugs explained
the change in CoV of stride time. P-values <0.05 were
considered statistically significant. All statistics were per-
formed using SPSS (version 15.0; IBM, Inc., Chicago, IL)
and Stata (version 12.1; College Station, TX).
Results
There was no difference between groups for the time be-
tween baseline and follow-up assessments (P = 0.062)
(Table 1). Between-group comparisons showed that there
was a significant difference for MMSE score (P < 0.001)
and CoV of stride time after treatment (P = 0.035). De-
mented patients using memantine had a lower MMSE
score at baseline compared to those with CEIs (P < 0.001)
and to those without anti-dementia drug (P < 0.001).
Patients treated with memantine had a lower CoV of
stride time at follow-up assessment compared to those
with CEIs (P = 0.010). There was no significant difference
between groups for the other baseline characteristics.
Between-group comparison of the change in CoV of
stride time between baseline and at follow-up assess-
ment was significant (P = 0.038) but only patients with
memantine had a higher change compared to those with
CEIs (P = 0.010) (Figure 1). There was no significant
difference between participants without anti-dementia
drugs and those using CEIs (P = 0.288) and those using
memantine (P = 0.176).
As shown in Table 2, the ANCOVA showed that
anti-dementia drugs decreased CoV of stride time only










83.4 ± 6.3 0.189 - - -
25 (61.0) 0.633 - - -
26.1 ± 4.5 0.763 - - -
6.0 ± 3.1 0.267 - - -
12 (29.3) 0.348
14.7 ± 4.3 <0.001 0.169 <0.001 <0.001
86.7 ± 96.2 0.062 - - -
0.9 ± 22.8 0.466 - - -
6.1 ± 5.0 0.699 - - -
4.2 ± 2.4 0.035 0.084 0.647 0.010
ental State Examination; CoV: coefficient of variation; SD: standard deviation;
e Chi-square test, as appropriate; †: benzodiazepines, antidepressants or neu-
-value significant (i.e., <0.05) indicated in bold.
Figure 1 Mean value and standard deviations of change in CoV of stride time between before and after treatment according to
treatment groups (n=120). CEIs: acetylcholinesterase inhibitors: CoV: coefficient of variation; *: Comparison based on Kruskal-Wallis test; †:
Comparison based on Mann-Whitney test.
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and P = 0.038 for full adjusted model). In final, mixed-
effects linear regressions underlined that anti-dementia
drug-related decrease in CoV of stride time was explained
by memantine (P = 0.028) but not CEIs (P > 0.250)
(Table 3). Moreover, full adjusted model showed that
female gender (P = 0.046) and a high MMSE score at
baseline assessment (P = 0.003) were associated with a
significant decrease of CoV of stride time.Table 2 Results of analysis of covariance with a repeated mea
anti-dementia drugs effect (i.e., no anti-dementia drug, acety
(i.e., time between before and after anti-dementia drugs intro




Anti-dementia drugs effect# 0.937 2.5
Time effect¶ 0.608 1.5




Number of drugs daily taken
Use of psychoactive drugs**
MMSE score††
Walking speed
CoV: coefficient of variation; BMI: body mass index; df: degree of freedom; MMSE: F
square-root and coded as a continuous variable, †: separated models (Model 1: non
conservative estimate; #: pool effect of acetylcholinesterase inhibitors and memanti
**: benzodiazepines, antidepressants or neuroleptics; ††: at baseline assessment (i.eDiscussion
Our results showed that memantine, but not CEIs, de-
creases gait variability in patients with ADRD. This
memantine-related improvement of gait variability was
shown few months after the first introduction of drug
and confirms a recent study reporting similar results
but without a comparison group with CEIs [7]. It may
be related to specific effects of memantine on both sub-
cortical and cortical levels of gait control. Indeed, thesures (n = 240) design analyzing the influence of
lcholinesterase inhibitors or memantine), time effect
duction) and their interaction on the coefficient Cov of
)
CoV of stride time*
† Model 2†
F P-value‡ df F
0.06 0.612 2.5 0.50
0.26 0.606 1.5 0.27








olstein's Mini-Mental State Examination; *: normalized by taking the
-adjusted on baseline characteristics; Model 2: full adjusted model); ‡: box
ne; ¶: time between before and after introduction of anti-dementia drugs;
., before treatment); P-value significant (i.e., P < 0.05) indicated in bold.
Table 3 Mixed-effects linear regressions predicting the change in CoV of stride time (n = 240 measures and n = 120
participants)
Change in CoV of stride time*
Model 1† Model 2†
β 95% CI P-value β 95% CI P-value
Drugs effect
Use of CEIs −0.067 [−0.381; 0.246] 0.674 −0.193 [−0.512; 0.125] 0.234
Use of memantine 0.179 [−0.138; 0.496] 0.268 −0.014 [−0.341; 0.313] 0.933
Time effect‡ 0.019 [−0.232; 0.269] 0.885 0.019 [−0.222; 0.259] 0.878
Drugs x time interaction
No treatment Ref Ref
Use of CEIs 0.186 [−0.153; 0.526] 0.282 0.190 [−0.138; 0.518] 0.256
Use of memantine −0.385 [−0.728; -0.415] 0.028 −0.371 [−0.702; -0.041] 0.028
Age 0.000 [−0.000; 0.000] 0.811
Female gender −0.229 [−0.453; -0.004] 0.046
BMI −0.0004 [−0.0000; 0.0008] 0.053
Number of drugs daily taken¶ 0.011 [−0.019; 0.041] 0.490
Use of psychoactive drugs#¶ 0.081 [−0.278; 0.116] 0.422
MMSE score¶ −0.028 [−0.046; -0.009] 0.003
Walking speed¶ −0.003 [−0.006; 0.0001] 0.147
CI = confidence interval; CEIs: acetylcholinesterase inhibitors; BMI: body mass index; MMSE: Folstein's Mini-Mental State Examination; CoV: coefficient of variation;
β: coefficient of regression beta corresponding to change in CoV of stride time; *: normalized by taking the square-root and coded as a continuous variable;
†: separated models (Model 1: non-adjusted on baseline characteristics; Model 2: full adjusted model); ‡: time between before and after introduction of
anti-dementia drugs; #: benzodiazepines, antidepressants or neuroleptics at baseline assessment; ¶: at baseline assessment (i.e., before treatment); P-value
significant (i.e., P < 0.05) indicated in bold.
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explained by its dopamergic effects, which improve
extrapyramidal motricity by acting on the dopamine D2
receptors [3,7]; but also by its glutamatergic effects on
the cognitive field, specifically the higher levels of gait
control [5,6,10]. Regarding to the progression of the
extrapyramidal syndrome during the course of ADRD
[17] and the fact that the patients treated with memantine
presented a lower MMSE, gait improvement presented
in this group could be related with a specific effect of
memantine on the extrapyramidal system.
No significant gait improvement with CEIs was shown
in our study. Opposite results were already published
about gait improvement due to CEIs. For instance, a CEIs-
related decrease in gait variability has been reported by
Montero-Odasso et al. while single- and dual-tasking [5].
However it is of note that, similarly to our results, there
were no significant changes in gait performance while
usual walking in patients treated with galantamine in Assal
et al.’s study [6]. In the latter study, the authors still
retained a gait improvement because non-treated controls
suffered a significant dual-task decrement in stride time
compared to cases using galantamine. These previous re-
sults suggested that CEIs could improve gait performance
mainly while dual-tasking rather than single-tasking. The
principle of the dual-task paradigm is to examine gaitperformance while simultaneously executing an attention-
demanding task [18]. Performance changes in dual-task
compared to single-task are usually interpreted as interfer-
ence due to competing demands for attention resources
needed for both tasks and mainly depend on one’s ability
to properly allocate attention between the two tasks
[9,11,18]. Previous results thus strengthen the idea that
CEIs may improve the cognitive component of gait, with
gait improvements especially identifiable in dual-task. As a
consequence, further research examining gait performance
while single- and dual-tasking is needed to better under-
stand the exact effects of memantine and CEIs on gait. In
final, our results showed that memantine-related decrease
in gait variability was associated with the level of global
cognitive functioning, a higher level being associated with
a greater decrease. This result may be explained by the
cognitive and motor effects of memantine, and under-
scores that, when ADRD is at a severe stage, symptomatic
effects of memantine are limited, probably because of the
diffuse neurodegenerative lesions in the brain.
Some limitations of this study need to be considered.
Firstly, the limited number of participants from one single
memory clinic may be unrepresentative of the general
population of patients with ADRD. Second, the pre-test/
post-test quasi-experimental open-label design with no
randomization of the assignment of participants into
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group, may limit the interpretation of our results. Third,
although we were able to control for the main charac-
teristics likely to modify the association between the
change of MMSE score and the double treatment arm,
residual confounders might still be present. Finally, add-
itional limitations lies in the failure to consider other
dementias such as vascular dementia and regarding the
improvement in the memantine group a regression to
the mean phenomenon can never be completely excluded
even if it seems unlikely.
Conclusion
In conclusion, we found a memantine-related decrease
in gait variability, and thus an improvement of gait
safety, among patients with ADRD. An ongoing double-
blind randomized placebo-controlled parallel group
intent-to-treat superiority clinical trial, the AD-IDEA
trial (ClinicalTrials.gov number: NCT01409694) [19], is
conducted to investigate whether the memantine-related
decrease in gait variability is confirmed.
Abbreviations
CEIs: Acetylcholinesterase inhibitors; ADRD: Alzheimer’s disease and related
disorders; ANCOVA: Analysis of covariance; CoV: Coefficient of variation;
MMSE: Mini mental status examination; NMDA: N-methyl-D-aspartate.
Competing interests
The study was financially supported by Lundbeck France pharmaceutical
company. The sponsors had no role in the design and conduct of the study,
in the collection, management, analysis, and interpretation of the data, or in
the preparation, review, or approval of the manuscript. All authors declare
that they have no competing interests.
Authors’ contributions
OB, CL and CA participated in designing the study, writing and reviewing of
the manuscript. GA, FRH, GW, KG participated in reviewing the manuscript.
All authors read and approved the final manuscript.
Acknowledgments
We are grateful to the participants for their cooperation.
Author details
1Department of Neuroscience, Division of Geriatric Medicine, UPRES EA 4638,
UNAM, Angers University Hospital, 49933 Angers cedex 9, France.
2Department of Neurology, Geneva University Hospital and University of
Geneva, Geneva, Switzerland. 3Department of Internal Medicine and
Geriatrics, Nancy University Hospital, Nancy, France. 4Department of
Geriatrics, Tourcoing Hospital, Tourcoing, France. 5Department of Internal
Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals and
University of Geneva, Geneva, Switzerland. 6Robarts Research Institute,
Department of Medical Biophysics, Schulich School of Medicine and
Dentistry, the University of Western Ontario, London, ON, Canada.
Received: 2 March 2013 Accepted: 28 October 2013
Published: 21 November 2013
References
1. Tsuno N: Donepezil in the treatment of patients with Alzheimer's
disease. Expert Rev Neurother 2009, 9:591–598.
2. Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of
Alzheimer's disease: an update. Clin Interv Aging 2007, 2:17–32.
3. McKeage K: Memantine: a review of its use in moderate to severe
Alzheimer's disease. CNS Drugs 2009, 23:881–897.4. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M: Can cognitive
enhancers reduce the risk of falls in older people with mild cognitive
impairment? A protocol for a randomised controlled double blind trial.
BMC Neurol 2009, 9:42.
5. Montero-Odasso M, Wells J, Borrie M: Can cognitive enhancers reduce the
risk of falls in people with dementia? An open-label study with controls.
J Am Geriatr Soc 2009, 57:359–360.
6. Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O: Galantamine
improves gait performance in patients with Alzheimer's disease. J Am
Geriatr Soc 2008, 56:946–947.
7. Beauchet O, Allali G, Launay C, Fantino B, Annweiler C: Does memantine
improve the gait of individuals with Alzheimer's disease? J Am Geriatr Soc
2011, 59:2181–2182.
8. Annweiler C, Beauchet O, Bartha R, Wells JL, Borrie MJ, Hachinski V,
Montero-Odasso M: Motor cortex and gait in mild cognitive impairment:
a magnetic resonance spectroscopy and volumetric imaging study.
Brain 2013, 136:859–871.
9. Beauchet O, Annweiler C, Montero-Odasso M, Fantino B, Herrmann FR, Allali
G: Gait control: a specific subdomain of executive function? J Neuroeng
Rehabil 2012, 9:12.
10. Rosano C, Brach J, Longstreth WT Jr, Newman AB: Quantitative measures
of gait characteristics indicate prevalence of underlying subclinical
structural brain abnormalities in high-functioning older adults.
Neuroepidemiology 2006, 26:52–60.
11. Beauchet O, Allali G, Annweiler C, Bridenbaugh S, Assal F, Kressig RW,
Herrmann FR: Gait variability among healthy adults: low and high
stride-to-stride variability are both a reflection of gait stability.
Gerontology 2009, 55:702–706.
12. Almeida QJ, Frank JS, Roy EA, Patla AE, Jog MS: Dopaminergic modulation
of timing control and variability in the gait of Parkinson's disease.
Mov Disord 2007, 22:1735–1742.
13. Ebersbach G, Baas H, Csoti I, Müngersdorf M, Deuschl G: Scales in
Parkinson's disease. J Neurol 2006, 253:iv32–iv35.
14. Shah A, Herbert R, Lewis S, Mahendran R, Platt J, Bhattacharyya B: Screening
for depression among acutely ill geriatric inpatients with a short
geriatric depression scale. Age Ageing 1997, 26:217–221.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group
under the auspices of department of health and human services task force
on Alzheimer's disease. Neurology 1984, 34:939–944.
16. Kressig RW, Beauchet O: Guidelines for clinical applications of spatio-
temporal gait analysis in older adults. Aging Clin Exp Res 2006, 18:174–176.
17. Stavitsky K, Brickman AM, Scarmeas N, Torgan RL, Tang MX, Albert M, Brandt J,
Blacker D, Stern Y: The progression of cognition, psychiatric symptoms, and
functional abilities in dementia with Lewy bodies and Alzheimer disease.
Arch Neurol 2006, 63:1450–1456.
18. Beauchet O, Allali G, Berrut G, Hommet C, Dubost V, Assal F: Gait analysis in
demented subjects: Interests and perspectives. Neuropsychiatr Dis Treat
2008, 4:155–160.
19. Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O:
Alzheimer's disease–input of vitamin D with mEmantine assay (AD-IDEA
trial): study protocol for a randomized controlled trial. Trials 2011, 12:230.
doi:10.1186/1471-2377-13-184
Cite this article as: Beauchet et al.: Anti-dementia drugs and changes in
gait: a pre-post quasi-experimental pilot study. BMC Neurology 2013 13:184.
